BFRI

Over the past six months, Biofrontera regained compliance with Nasdaq's listing requirements. The FDA accepted the sNDA filing for Ameluz® PDT in superficial basal cell carcinoma. The U.S. Patent Office ruled Sun Pharma's patent claims unpatentable. Positive Phase 2b results supported Ameluz® Photodynamic Therapy development for acne vulgaris. The company reported record fourth quarter and full year 2025 financial results, with revenues expected to grow by approximately 11% to 13%.